Key result
Aprindine abolishes SVT inducibility and relieves symptoms in refractory WPW cases.
Why the study?
Patients with supraventricular tachycardia associated with Wolff-Parkinson-White syndrome refractory to conventional pharmacological therapy require alternative treatment options.
Does aprindine improve symptoms and reduce inducibility of supraventricular tachycardia in patients with Wolff-Parkinson-White syndrome refractory to conventional therapy?
Case Report (n=4)
Does aprindine improve symptoms and reduce inducibility of supraventricular tachycardia in patients with Wolff-Parkinson-White syndrome refractory to conventional therapy?
Aprindine is effective in suppressing refractory supraventricular tachycardia in patients with Wolff-Parkinson-White syndrome.
Aprindine may benefit refractory WPW; extends sparse case data but leaves open need for randomized confirmation.
Four patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome were refractory to conventional pharmacological therapy and received aprindine hydrochloride intravenously and orally. Electrophysiological studies disclosed that intravenous aprindine caused increased refractoriness and slowed conduction in the atria, atrioventricular node, ventricles, and accessory pathway. The ability to induce supraventricular tachycardia with timed atrial and ventricular premature stimuli was totally abolished in all 4 patients after intravenous aprindine. Oral aprindine therapy, twice daily thereafter, provided symptomatic relief of the supraventricular tachycardia without significant side effects. Aprindine is useful in the management of supraventricular tachycardia associated with Wolff-Parkinson-White and may offer significant advantages over currently available therapy.
No takes yet. Share an insight, caveat, or question.
Reid et al. (1977) conducted a case report in Supraventricular tachycardia associated with Wolff-Parkinson-White syndrome (n=4). Aprindine hydrochloride was evaluated on Ability to induce supraventricular tachycardia with timed atrial and ventricular premature stimuli. Intravenous and oral aprindine abolished the ability to induce supraventricular tachycardia and provided symptomatic relief without significant side effects in 4 refractory WPW patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: